OS Therapies Inc (OSTX) stock
Close on Nov 12, 2026Market cap $34.60MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $34.60M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$39.37M
- EPS, diluted
- -$1.07
- Free cash flow
- -$14.70M
- Book value per share
- -$0.27
- Diluted shares
- 44M
Trading
- Previous close
- $0.87
- Open
- $0.88
- Day's range
- $0.72 – $0.88
- Volume
- 1,339,568
- Average volume (20 days)
- 651,646
- Beta (5 years)
- 0.33
- 52-week range
- $0.58 – $2.25
- RSI (14 days)
- 16.6
- Volatility (1 year)
- 76.9%
- Relative volume
- 2.21×
- WACC
- 7.4%
Market cap history
Month-end market cap since 2024, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | OSTX | S&P 500 | Difference | OSTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -51.9% | -2.7% | −49.2 pts | ||
| 3 months | -53.4% | -1.7% | −51.7 pts | ||
| Year to date | -46.4% | +11.9% | −58.3 pts | ||
| 1 year | -60.9% | +12.0% | −72.9 pts |
Four years at a glance
Fiscal years 2022 to 2025 and trailing twelve months, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases OS Therapies filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- News
- Update
- Update
- News
About OS Therapies
Pharmaceutical Preparations
OS Therapies Incorporated is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments for osteosarcoma and other solid tumors. Its pipeline features two core technologies: OST-HER2, an off-the-shelf immunotherapy utilizing an attenuated strain of Listeria monocytogenes to stimulate an immune response against HER2-expressing cancer cells, and a preclinical tunable antibody-drug conjugate platform known as OST-tADC. Beyond human oncology indications such as pediatric osteosarcoma, breast, lung, and esophageal cancers, the company explores veterinary applications in canines. Its intended patient populations include children, young adults, and older patients diagnosed with bone and solid cancers.
Company profile, executives and historyOS Therapies stock: common questions
What is OS Therapies's stock price?
OSTX closed at $0.75 on Nov 12, 2026, down 14.00% on the day. Over the past 52 weeks it traded between $0.58 and $2.25.
What is OS Therapies's market cap?
OS Therapies was worth $34.60M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is OSTX's P/E ratio?
OS Therapies lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.07), so it has no meaningful P/E ratio.
Does OS Therapies pay a dividend?
No. OS Therapies has not paid a cash dividend over the last twelve months.
How has OSTX stock performed over the past year?
Including dividends, OSTX returned -60.9% over the past year, against +12.0% for the S&P 500.
How many OSTX shares are sold short?
3M shares were sold short at the latest FINRA report, 6.92% of the float, or 7.7 days of average trading volume.
Who are OS Therapies's competitors?
Companies most similar to OS Therapies by business, industry and size include TOVX, APVO, IMNM, CLRB, NWBO.
See a number that looks wrong?